← See all news items

SynGenX®-1000 System Adopted by Anthony Nolan Cell Therapy Centre

SynGen Announces the first Cord Blood Center to Adopt their Cord Blood Processing System

June 11, 2015   |   Sacramento, CA   |   PR Newswire


lg_syngenx1000SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that, after extensive review of competitive systems, The Anthony Nolan Cell Therapy Centre in Nottingham UK has chosen the SynGenX®-1000 System and the CryoPRO™ Workstation to process its umbilical cord blood units.  Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen Inc.’s UK distributor, for the supply of SynGen’s products and all post-sales support, starting late summer 2015.

The state-of-the-art SynGenX-1000 System harvests the stem and progenitor cells from collected units of umbilical cord blood.  The CryoPRO™ Workstation protects the precious cells as they are prepared for freezing and storage in the novel CryoPRO-2 Cryopreservation/Storage Bag Set.  The SynGenX-1000 System has received 510(k) clearance from the FDA for sale in the United States, and is CE marked for sale in the UK and the European Union.

CryoPRO Workstation “In our hands, the SynGen system demonstrated the highest recovery of viable stem and progenitor cells of the available systems,” said Dr. Susana Gomez, Head of the Anthony Nolan Cord Blood Bank and Senior Research Scientist.   “We look forward to a long and productive relationship with both SynGen and Deva Medical that will benefit patients who require a transplant.”

“We are proud to be associated with the prestigious Anthony Nolan Cell Therapy Centre and are pleased that their testing has demonstrated both high total nuclear cell counts (TNCs) and virtually 100% recoveries of critical CD 34+ cells in the final product using the SynGenX-1000 System,” said Frank Pascale, President of the SynGen Cord Blood Business Unit.  “We look forward to supporting Anthony Nolan’s goal of providing them with the best possible cord blood units for transplant.”

Jason Betteley, Director at Deva Medical, said, “Deva Medical and SynGen are extremely excited to have won this new 5-year contract with The Anthony Nolan Cell Therapy Centre.  We are equally excited to be the distributor of the SynGenX-1000 System for SynGen throughout the EU.  We continue to be extremely impressed with the high standard of expertise and professionalism of everyone at SynGen and look forward to a long relationship with both SynGen and Anthony Nolan.”

To download a copy of this press release, please click here.